Dr. Hui Tian is currently a Venture Partner at The Column Group (TCG). TCG is a science driven venture capital firm that focuses on building early-stage biopharmaceutical companies. Dr. Tian is responsible for identifying exciting new ideas and forming companies around these ideas in collaboration with entrepreneurs. Previously he was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research. In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer. In a span of 14 years, he led the discovery and advancement of more than a dozen clinical candidates, mostly antibody-based therapeutics. Prior to NGM, he was a Scientific Director at Amgen and Tularik leading discovery research in the areas of metabolic disorders and orphan G protein-coupled receptors. Dr. Tian received a Ph.D. in Molecular and Cellular Biology at the University of Texas Southwestern Medical Center and did his post-doctoral training at Harvard University.